The natriuretic peptides as biomarkers for adults with congenital heart disease

Biomarkers in Medicine

Volumn 6, Issue 6, 2012, Pages 827-837

  Nir, Amiram ^a   Luchner, Andreas ^b   Rein, Azaria Jjt ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

adult; B type natriuretic peptide; congenital; Eisenmenger; Fontan; heart; natriuretic peptides; pregnancy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; SILDENAFIL;

CONGENITAL HEART DISEASE; CYANOTIC HEART DISEASE; DIAGNOSTIC KIT; DISEASE SEVERITY; EISENMENGER COMPLEX; ENZYME ASSAY; FALLOT TETRALOGY; FONTAN PROCEDURE; GLOMERULUS FILTRATION RATE; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE OVERLOAD; HUMAN; KIDNEY DISEASE; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG RESISTANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; PATENT DUCTUS ARTERIOSUS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PULMONARY VALVE INSUFFICIENCY; PULMONARY VALVE STENOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TRICUSPID VALVE REGURGITATION;

ADULT; ANIMALS; BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDES; PROGNOSIS;

EID: 84870899997     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.73     Document Type: Review

References (68)

1. Baumgartner H, Bonhoeffer P, De Groot NM et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology; Association for European Paediatric Cardiology. Eur. Heart J. 31, 2915-2957 (2010
2. Warnes CA, Liberthson R, Danielson GK et al. Task force 1: The changing profile of congenital heart disease in adult life. J. Am. Coll. Cardiol. 37, 1170-1175 (2001
3. Bettencourt PM. Clinical usefulness of B-Type natriuretic peptide measurement: Present and future perspectives. Heart 91, 1489-1494 (2005
4. Das BB. Plasma B-Type natriuretic peptides in children with cardiovascular diseases. Pediatr. Cardiol. 31, 1135-1145 (2010
5. Koulouri S, Acherman RJ, Wong PC, Chan LS, Lewis AB. Utility of B-Type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr. Cardiol. 25, 341-346 (2004
6. Cantinotti M, Giovannini S, Murzi B, Clerico A. Diagnostic, prognostic and therapeutic relevance of B-Type natriuretic hormone and related peptides in children with congenital heart diseases. Clin. Chem. Lab. Med. 49, 567-580 (2011
7. Daniels LB, Maisel AS. Natriuretic peptides. J. Am. Coll. Cardiol. 50, 2357-2368 (2007
8. Buchner S, Jungbauer C, Birner C, Debl K, Riegger GA, Luchner A. Comparison of the cardiac markers B-Type natriuretic peptide and N-Terminal pro B-Type natriuretic peptide. Biomark. Med. 3, 465-481 (2009
9. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. J. Heart Fail. 10, 933-989 (2008
10. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. J. Heart Fail. 14(8), 803-869 (2012
11. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: Direct comparison of brain natriuretic peptide (BNP) and N-Terminal pro-BNP. Hypertension 46, 118-123 (2005
12. Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function on N-Terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the emergency department: Comparison with brain natriuretic peptide (BNP). Clin. Chim. Acta 361, 167-175 (2005
13. Nir A, Lindinger A, Rauh M et al. NT-pro-Btype natriuretic peptide in infants and children: Reference values based on combined data from four studies. Pediatr. Cardiol. 30, 3-8 (2009
14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J. Am. Coll. Cardiol. 40, 976-982 (2002
15. Prontera C, Zaninotto M, Giovannini S et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-Terminal part of the propeptide of BNP (NT-proBNP) immunoassays: The CardioOrmocheck study. Clin. Chem. Lab. Med. 47, 762-768 (2009
16. Bolger AP, Sharma R, Li W et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106, 92-99 (2002
17. Trojnarska O, Gwizdala A, Katarzynski S et al. Evaluation of exercise capacity with cardiopulmonary exercise test and B-Type natriuretic peptide in adults with congenital heart disease. Cardiol. J. 16, 133-141 (2009
18. Niedeggen A, Skobel E, Haager P, Lepper W, Muhler E, Franke A. Comparison of the 6-minute walk test with established parameters for assessment of cardiopulmonary capacity in adults with complex congenital cardiac disease. Cardiol. Young 15, 385-390 (2005
19. Kidd L, Driscoll DJ, Gersony WM et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 87(SUPPL2), I38-I51 (1993
20. Kunii Y, Kamada M, Ohtsuki S et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med. Okayama 57, 191-197 (2003
21. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr. Int. 45, 249-254 (2003
22. Nagaya N, Nishikimi T, Uematsu M et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am. Heart J. 136, 297-301 (1998
23. Trojnarska O, Szyszka A, Gwizdala A et al. Evaluation of exercise capacity with cardiopulmonary exercise testing and type B natriuretic peptide concentrations in adult patients with patent atrial septal defect. Cardiology 106, 154-160 (2006
24. Schoen SP, Zimmermann T, Kittner T et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur. J. Heart Fail. 9, 660-666 (2007
25. Koch AM, Zink S, Glöckler M, Seeliger T, Dittrich S. Plasma levels of B-Type natriuretic peptide in patients with tetralogy of Fallot after surgical repair. Int. J. Cardiol. 143, 130-134 (2010
26. Lemmer J, Heise G, Rentzsch A et al.; The German Competence Network for Congenital Heart Defects. Right ventricular function in grown-up patients after correction of congenital right heart disease. Clin. Res. Cardiol. 100, 289-296 (2011
27. Norozi K, Buchhorn R, Kaiser C et al. Plasma N-Terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair. Chest 128, 2563-2570 (2005
28. Festa P, Ait-Ali L, Prontera C et al. Aminoterminal fragment of pro-brain natriuretic hormone identifies functional impairment and right ventricular overload in operated tetralogy of Fallot patients. Pediatr. Cardiol. 28, 339-345 (2007
29. Dodge-Khatami A, Buchel EV, Knirsch W et al. Brain natriuretic peptide and magnetic resonance imaging in tetralogy with right ventricular dilatation. Ann. Thorac. Surg. 82, 983-988 (2006
30. Oosterhof T, Tulevski II, Vliegen HW, Spijkerboer AM, Mulder BJ. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of Fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-Type natriuretic peptide levels. Am. J. Cardiol. 97, 1051-1055 (2006
31. Apitz C, Sieverding L, Latus H, Uebing A, Schoof S, Hofbeck M. Right ventricular dysfunction and B-Type natriuretic peptide in asymptomatic patients after repair for tetralogy of Fallot. Pediatr. Cardiol. 30, 898-904 (2009
32. Graham TP Jr, Markham LW. Congenitally corrected transposition of the great arteries. In: Diagnosis and Management of Adult Congenital Heart Disease. Gatzoulis MA, Webb GD, Daubeney PEF (Eds). Elsevier, PA, USA, 371-377 (2011
33. Tulevski II, Groenink M, van Der Wall EE et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: Correlation between plasma neurohormones and right ventricular dysfunction. Heart 86, 27-30 (2001
34. Chow PC, Cheung EW, Chong CY et al. Brain natriuretic peptide as a biomarker of systemic right ventricular function in patients with transposition of great arteries after atrial switch operation. Int. J. Cardiol. 127, 192-197 (2008
35. Szymanski P, Klisiewicz A, Lubiszewska B et al. Application of classic heart failure definitions of asymptomatic and symptomatic ventricular dysfunction and heart failure symptoms with preserved ejection fraction to patients with systemic right ventricles. Am. J. Cardiol. 104, 414-418 (2009
36. Vogt M, Kuhn A, Wiese J, Eicken A, Hess J, Vogel M. Reduced contractile reserve of the systemic right ventricle under dobutamine stress is associated with increased brain natriuretic peptide levels in patients with complete transposition after atrial repair. Eur. J. Echocardiogr. 10, 691-694 (2009
37. Koch AM, Zink S, Singer H, Dittrich S. B-Type natriuretic peptide levels in patients with functionally univentricular hearts after total cavopulmonary connection. Eur. J. Heart Fail. 10, 60-62 (2008
38. Plymen CM, Hughes ML, Picaut N et al. The relationship of systemic right ventricular function to ECG parameters and NT-proBNP levels in adults with transposition of the great arteries late after Senning or Mustard surgery. Heart 96, 1569-1573 (2010
39. Garg R, Raman SV, Hoffman TM, Hayes J, Daniels CJ. Serum markers of systemic right ventricular function and exercise performance. Pediatr. Cardiol. 29, 641-648 (2008
40. Cowley CG, Bradley JD, Shaddy RE. B-Type natriuretic peptide levels in congenital heart disease. Pediatr. Cardiol. 25, 336-340 (2004
41. Hama N, Itoh H, Shirakami G et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92, 1558-1564 (1995
42. Budweiser S, Luchner A, Jörres RA et al. NT-proBNP in chronic hypercapnic respiratory failure: A marker of disease severity, treatment effect and prognosis. Respir. Med. 101, 2003-2010 (2007
43. Lin NC, Landt ML, Trinkaus KM, Balzer DT, Kort HW, Canter CE. Relation of age, severity of illness, and hemodynamics with brain natriuretic peptide levels in patients <20 years of age with heart disease. Am. J. Cardiol. 96, 847-850 (2005
44. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: Enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 109, 2872-2877 (2004
45. Diller GP, Alonso-Gonzalez R, Kempny A et al. B-Type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: Predictive value and response to disease targeting therapy. Heart 98, 736-742 (2012
46. Khairy P, Fernandes SM, Mayer JE et al. Long-Term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117, 85-92 (2008
47. Kairy P, Mercier LA. Late complications following the Fontan operation In: Diagnosis and Management of Adult Congenital Heart Disease. Gatzoulis MA, Webb GD, Daubeney PEF (Eds). Elsevier, PA, USA, 104-109 (2011
48. Hjortdal VE, Stenbog EV, Ravn HB et al. Neurohormonal activation late after cavopulmonary connection. Heart 83, 439-443 (2000
49. Holmgren D, Stromvall-Larsson E, Lundberg PA, Eriksson BO, Wahlander H. Brain natriuretic peptide assessed at long-Term follow-up before and after maximal exercise in surgically palliated patients with functionally univentricular hearts. Cardiol. Young 17, 505-511 (2007
50. Ohuchi H, Takasugi H, Ohashi H et al. Abnormalities of neurohormonal and cardiac autonomic nervous activities relate poorly to functional status in Fontan patients. Circulation 110, 2601-2608 (2004
51. Hager A, Christov F, Hess J. Increase in N-Terminus-pro-B-Type natriuretic peptide during exercise of patients with univentricular heart after a total cavopulmonary connection. Pediatr. Cardiol. 33, 764-769 (2012
52. Law YM, Keller BB, Feingold BM, Boyle GJ. Usefulness of plasma B-Type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am. J. Cardiol. 95, 474-478 (2005
53. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J. Characterization of brain natriuretic peptide in long-Term follow-up of pulmonary arterial hypertension. Chest 128, 2368-2374 (2005
54. Nagaya N, Nishikimi T, Okano Y et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J. Am. Coll. Cardiol. 31, 202-208 (1998
55. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102, 865-870 (2000
56. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial. Eur. Heart J. 31, 1124-1131 (2010
57. Kermeen FD, Franks C, O'Brien K et al. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart Lung Circ. 19, 595-600 (2010
58. D'Alto M, Romeo E, Argiento P et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int. J. Cardiol. 22(155), 378-382 (2012
59. D'Alto M. Brain natriuretic peptide, survival and response to targeting therapy: Another piece in the complex puzzle of Eisenmenger syndrome. Heart 98, 681-682 (2012
60. Veldtman GR, Connolly HM, Grogan M, Ammash NM, Warnes CA. Outcomes of pregnancy in women with Tetralogy of Fallot. J. Am. Coll. Cardiol. 44, 174-180 (2004
61. Drenthen W, Pieper PG, Roos-Hesselink JW et al. Outcome of pregnancy in women with congenital heart disease: A literature review. J. Am. Coll. Cardiol. 49, 2303-2311 (2007
62. Hameed AB, Chan K, Ghamsary M, Elkayam U. Longitudinal changes in the B-Type natriuretic peptide levels in normal pregnancy and postpartum. Clin. Cardiol. 32, E60-E62 (2009
63. Tanous D, Siu SC, Mason J et al. B-Type natriuretic peptide in pregnant women with heart disease. J. Am. Coll. Cardiol. 56, 1247-1253 (2010
64. Giannakoulas G, Dimopoulos K, Bolger AP et al. Usefulness of natriuretic peptide levels to predict mortality in adults with congenital heart disease. Am. J. Cardiol. 105, 869-873 (2010
65. Jungbauer CG, Riedlinger J, Buchner S et al. High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-Terminal pro-B-Type natriuretic peptide. Clin. Chem. Lab. Med. 49, 1899-1906 (2011
66. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: A meta-Analysis of randomized controlled trials. Am. Heart J. 158, 422-430 (2009
67. Ishii H, Harada K, Toyono M, Tamura M, Takada G. Usefulness of exercise-Induced changes in plasma levels of brain natriuretic peptide in predicting right ventricular contractile reserve after repair of tetralogy of Fallot. Am. J. Cardiol. 95, 1338-1343 (2005
68. Holmgren D, Westerlind A, Berggren H, Lundberg PA, Wåhlander H. Increased natriuretic peptide type B level after the second palliative step in children with univentricular hearts with right ventricular morphology but not left ventricular morphology. Pediatr. Cardiol. 29, 786-792 (2008